Long Xiangyu, Zhou Wei, Wang Yuanxing, Liu Shiqiang
Department of Oncology, West China Guang'an Hospital, Sichuan University, Guang'an, Sichuan 638000, P.R. China.
Department of Cardiothoracic Surgery, Nanchong Central Hospital, The Second Clinical College of North Sichuan Medical College, Nanchong, Sichuan 637900, P.R. China.
Oncol Lett. 2018 Aug;16(2):1835-1840. doi: 10.3892/ol.2018.8858. Epub 2018 May 31.
Anillin actin binding protein (ANLN) is a biomarker of cancer progression and is overexpressed in lung adenocarcinoma. The aim of the present study was to investigate the role of ANLN protein and RNA in the development of lung adenocarcinoma. The ANLN protein sequence was downloaded from The National Centre for Biotechnology information, RNA sequencing (RNA-seq) data was obtained from The Cancer Genome Atlas database. All immunohistochemical staining pictures were adapted from the Human Protein Atlas. PyMOL software was employed to predict protein functional changes in response to mutations. Gene Set Enrichments Analysis was employed for pathway analysis. The results indicated that ANLN experiences genetic change and overexpression at the RNA and protein levels in patients with lung adenocarcinoma. Kaplan-Meier survival curve analysis revealed significant differences between high and low RNA-seq expression levels in ANLN, and patients exhibiting higher expression of ANLN had a relatively poor prognosis. Pathway analysis demonstrated that ANLN was involved in developmental processes via the regulation of nuclear division' pathway. In conclusion, ANLN has potential for use as a diagnostic and prognostic biomarker to diagnoseand predict the outcome of lung adenocarcinoma.
锚蛋白（Anillin）肌动蛋白结合蛋白（ANLN）是癌症进展的生物标志物，在肺腺癌中过表达。本研究的目的是探讨ANLN蛋白和RNA在肺腺癌发生发展中的作用。ANLN蛋白序列从美国国立生物技术信息中心下载，RNA测序（RNA-seq）数据从癌症基因组图谱数据库获得。所有免疫组化染色图片均取自人类蛋白质图谱。使用PyMOL软件预测蛋白质因突变产生的功能变化。采用基因集富集分析进行通路分析。结果表明，肺腺癌患者的ANLN在RNA和蛋白质水平上发生基因变化并过表达。Kaplan-Meier生存曲线分析显示，ANLN的RNA-seq高表达水平和低表达水平之间存在显著差异，ANLN表达较高的患者预后相对较差。通路分析表明，ANLN通过调节“核分裂”通路参与发育过程。总之，ANLN有潜力作为诊断和预后生物标志物用于诊断和预测肺腺癌的预后。
